公开(公告)号：US20200299329A1

公开(公告)日：2020-09-24

申请号：US16823356

申请日：2020-03-19

Applicant: Academia Sinica

Inventor： Han-Chung WU ,  Yuan-Sung KUO

IPC: C07K7/06 ,  A61K47/64 ,  A61K38/43

Abstract: Disclosed herein is a biomolecule comprising a synthetic peptide for targeting thrombus, a pharmaceutical composition comprising the same, and uses thereof in the treatment of thromboembolism-related diseases. According to embodiments of the present disclosure, the synthetic peptide having the amino acid sequence of SEQ ID NO: 1, 2, or 3 exhibits a binding affinity and specificity to thrombus. Thus, the synthetic peptide may serve as a targeting element for delivering a therapeutic agent (e.g., an anticoagulant agent or a thrombolytic agent) to the thrombus thereby improving the therapeutic safety and efficacy of the therapeutic agent.

公开(公告)号：US20180265590A1

公开(公告)日：2018-09-20

申请号：US15982141

申请日：2018-05-17

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Chung-Yi WU ,  Che MA ,  Han-Chung WU

IPC: C07K16/30 ,  A61K45/06 ,  C07K16/28 ,  C12P21/00 ,  C07K16/18

CPC classification number: C07K16/30 ,  A61K45/06 ,  C07K16/1018 ,  C07K16/18 ,  C07K16/241 ,  C07K16/2887 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00 ,  C12N9/24 ,  C12P21/005 ,  C12Y302/01 ,  C12Y302/01051

Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.

公开(公告)号：US20160102151A1

公开(公告)日：2016-04-14

申请号：US14798312

申请日：2015-07-13

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Tsui-Ling HSU ,  Yi-Wei LOU ,  Chih-Wei LIN ,  Shih-Chi YEH ,  Chung-Yi WU ,  Han-Chung WU

IPC: C07K16/44 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K16/44 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/57407 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2400/00 ,  G01N2405/10 ,  G01N2800/52

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

公开(公告)号：US20220403044A1

公开(公告)日：2022-12-22

申请号：US17756022

申请日：2020-11-16

Applicant: ACADEMIA SINICA

Inventor： Han-Chung WU ,  Hao-Nien CHEN

IPC: C07K16/30 ,  A61P35/00 ,  A61P11/00 ,  C07K16/28 ,  A61P15/00 ,  A61P1/00 ,  C12N15/113

Abstract: The present disclosure relates to therapeutic use of anti-EpCAM antibodies. Also provided is a combination immune therapy of an anti-EpCAM antibody and a PD-L1 immune checkpoint inhibitor.

公开(公告)号：US20210324335A1

公开(公告)日：2021-10-21

申请号：US17273256

申请日：2019-09-03

Applicant: ACADEMIA SINICA

Inventor： Han-Chung WU ,  I-I KUAN ,  Chien-Hsu CHEN

IPC: C12N5/0775

Abstract: The present invention generally relates to a medium composition and method for culturing mesenchymal stem cells (MSCs), in which the medium comprises an epithelial cell adhesion molecule (EpCAM) peptide, particularly a truncated EpCAM polypeptide containing the extracellular domain (EpEX). It significantly enhances cell proliferation and multipotency of the MSCs.

公开(公告)号：US20180127504A1

公开(公告)日：2018-05-10

申请号：US15563950

申请日：2016-04-12

Applicant: Academia Sinica

Inventor： Han-Chung WU ,  Ruei-Min LU ,  Chiung-Yi CHIU ,  I-Ju LIU ,  Yu-Ling CHANG

IPC: C07K16/28 ,  A61K31/337 ,  A61K39/395 ,  C07K16/30 ,  A61P35/00 ,  A61P35/02 ,  G01N33/574

CPC classification number: C07K16/2863 ,  A61K31/337 ,  A61K39/3955 ,  A61K2039/505 ,  A61P35/00 ,  A61P35/02 ,  C07K16/22 ,  C07K16/30 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/531 ,  G01N33/57492 ,  G01N2333/71 ,  A61K2300/00

Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

公开(公告)号：US20160289340A1

公开(公告)日：2016-10-06

申请号：US15011543

申请日：2016-01-30

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Tsui-Ling HSU ,  Yi-Wei LOU ,  Chih-Wei LIN ,  Shih-Chi YEH ,  Chung-Yi WU ,  Han-Chung WU ,  Han-Chung WU

IPC: C07K16/44

CPC classification number: C07K16/44 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/57407 ,  G01N2800/52

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

Abstract translation: 本文公开了包含与globo H，SSEA3和SSEA-4结合的抗体或其抗原结合片段的药物组合物及其使用方法。 使用的方法包括但不限于癌症治疗和诊断。 本公开的抗体可以结合某些癌细胞表面。 本文公开的抗体的示例性靶标可以包括癌，例如脑，皮肤，骨，肺，乳腺，食道，胃，肝，胆管，胰腺，结肠，肾，子宫颈，卵巢和/或前列腺癌中的那些。

公开(公告)号：US20150202316A1

公开(公告)日：2015-07-23

申请号：US14599291

申请日：2015-01-16

Applicant: Academia Sinica

Inventor： Han-Chung WU ,  Yi-Hsuan CHI

IPC: A61K47/48 ,  G01N33/574 ,  A61K31/704

CPC classification number: A61K47/48246 ,  A61K31/704 ,  A61K47/48815 ,  A61K47/64 ,  A61K47/6911 ,  G01N33/57423 ,  G01N2458/00

Abstract: A conjugate is disclosed. The conjugate comprises (a) an isolated or a synthetic targeting peptide of less than 15 amino acid residues in length, comprising an amino acid sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 1-8; and (b) a component conjugated to the targeting peptide, the component being selected from the group consisting of a drug delivery vehicle, an anti-cancer drug, a micelle, a nanoparticle, a liposome, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a cell, an imaging agent, and a labeling agent. Methods of treating lung cancer and detecting lung cancer cells are also disclosed.

Abstract translation: 公开了缀合物。 缀合物包含（a）长度小于15个氨基酸残基的分离或合成的靶向肽，其包含与选自SEQ ID NO：1-8的序列具有至少90％同一性的氨基酸序列 ; 和（b）与靶向肽缀合的组分，该组分选自药物递送载体，抗癌药物，胶束，纳米颗粒，脂质体，聚合物，脂质，寡核苷酸， 肽，多肽，蛋白质，细胞，成像剂和标记试剂。 还公开了治疗肺癌和检测肺癌细胞的方法。